Previous close | 0.5850 |
Open | 0.6000 |
Bid | 0.6000 x N/A |
Ask | 0.6500 x N/A |
Day's range | 0.6000 - 0.6250 |
52-week range | 0.4600 - 0.9900 |
Volume | |
Avg. volume | 91,644 |
Market cap | 56.131M |
Beta (5Y monthly) | 2.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company), a developer of next-generation exosome solutions and precision diagnostics, is pleased to announce excellent results from an independent clinical validation study of its SubB2M/CA15-3 test for breast cancer detection. The study showed high accuracy (87%), sensitivity (81%), and specificity (93%) for INOVIQ's SubB2M test, outperforming a leading approved CA15-3 test.